Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

Overview of attention for article published in Cancer Discovery, February 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 5 news outlets

twitter: 48 X users

Readers on

mendeley: 9 Mendeley

Summary News X

So far, Altmetric has seen 71 X posts from 48 X users, with an upper bound of 572,535 followers.

RT @RUIDH1bS5C7VQAH: 抗HER2バイスペシフィック抗体のZanidatamab治療前後の腫瘍検体で樹立したPDXモデルをつかったBed to bench study。MET amplificationが獲得耐性機序の候補であることが示され、Zanidatam…

03 Sep 2024

Reply Repost Favourite

抗HER2バイスペシフィック抗体のZanidatamab治療前後の腫瘍検体で樹立したPDXモデルをつかったBed to bench study。MET amplificationが獲得耐性機序の候補であることが示され、Zanidatamab＋MET阻害薬による耐性克服の可能性が示された https://t.co/zm1QOGKIaE

02 Sep 2024

Reply Repost Favourite

RT @InnovOncology: Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts @CD_AACR @ElizSMcKe…

12 Jul 2024

Reply Repost Favourite

RT @InnovOncology: Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts @CD_AACR @ElizSMcKe…

12 Jul 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 67 additional X posts.